4. Biogen Idec
4. Biogen Idec
Fortune 500 rank: 476
2011 revenue: $5.0 billion
2011 total shareholder return: 64.1%
Ticker: BIIB

An experimental drug poised to become the world's leading treatment for multiple sclerosis got investors excited about this Massachusetts-based drug-maker. Shares of Biogen Idec surged after studies showed the effectiveness of BG-12, which analysts estimate could generate up to $3 billion in annual sales.

Under relatively new CEO George Scangos, Biogen reported robust earnings. For 2011, profits rose by 23% to $1.23 billion or $5.04 per share. And Scangos was handsomely rewarded for that performance. He earned $11.3 million in salary, bonus and stock awards.

By Nin-Hai Tseng @FortuneMagazine - Last updated May 07 2012: 10:52 AM ET
Join the Conversation
Biggest stock losers

Investors in these Fortune 500 companies saw devastating losses

Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.